Navigation Links
NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:8/27/2007

SAN CARLOS, Calif., Aug. 27 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the 2007 NewsMakers in the Biotech Industry Conference on Thursday, September 6, 2007. Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer, will be presenting.

Date: Thursday, September 6, 2007

Time: 2:00 p.m. ET

Place: Millennium Broadway Hotel, New York, NY

An audio Web cast of the Company's presentation will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy. NeurogesX's late stage product portfolio is led by product candidate NGX-4010, a topical patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Two Phase 3 clinical trials with NGX-4010 have been completed and
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...TEO, Calif., Nov. 6 ,... transfer of Qutenza(TM) E.U. Marketing Authorizat...ant progress in commercial readiness activities E...r Director, Marketing; and Director, Commercial Op...s director and Audit Committee chairman , U...
(Date:11/6/2009)... The agenda for Arrowhead’s 201...hich is set to take place on February 22-24, 2010 ... day conference we will highlight key issues in fo... share their experiences. , ... agenda for Arrowhead’s 2010 Personalized M...
(Date:11/5/2009)...PANY, N.J., Nov. 5 DSM Pharmaceuti...nufacturing alliance with Galenix, Saint Jean D,Il...rcial scale manufacturing partner for Galenix comm...alenix will collaborate on business development op...hnologies, based on the strength of Galenix in dru...
(Date:11/5/2009)... Neb., Nov. 5 Transgenom...d financial results for the quarter ended Septembe...esented in the tables that follow. ,, Third Qu...of $366,000 or $0.01 per share for the third quart...r $0.01 per share for the third quarter of 2008. ...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...fe Sciences,announced today that Richard Evans has...sibility will be providing advisory services to co... as well as selected investment,assignments in cap...ted,drug analyst, he will also have responsibility... in the capital markets area. "Richard brings us ...
... Presentations Accepted to Meeting, CAMBRIDGE, Ma...oday announced that 23 presentations will showcase...ts antibiotic drug discovery,platform at the upcom...robial Agents and Chemotherapy (ICAAC), taking pla... Ph.D., Chief Scientific Officer of Targanta Thera...
...al Partners and Versant Ventures Lead ...DISON, Wis., Sept. 12 OpGen, Inc., today announce...ity financing. The round,was led by CHL Medical Pa...ures, with previous investor Mason Wells also part...ecome chairman of the Board of,Directors and will ...
Other Biology Technology:Senior Research Analyst Richard Evans Joins AVOS Life Sciences 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 3Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 4Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 5Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 6Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 7OpGen Announces $23.6 Million Series A Financing 2OpGen Announces $23.6 Million Series A Financing 3
(Date:11/9/2009)...s have had their hands tied because more than half...a protein called p53. As a critical anti-cancer wa...erations within cells. When cells lose p53, tumors..., These tumors might be tough, but they,re not in...rbor Laboratory (CSHL). The chink in the tumors, a...
(Date:11/9/2009)...has inspired a 3.2m, three-year research project t...f security, energy and the environment. The Univer...y QinetiQ have just signed a collaborative contrac...ing physical sciences research. , Over the next...ity of Exeter and QinetiQ will work together to de...
(Date:11/9/2009)...utritionist whose research was instrumental in add...fants and Children (WIC) food subsidy will receive...nding achievement in the field of maternal-fetal n...fessor in the Department of Community Health Scien...chool of Public Health, will receive the award to...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 1Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 2Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 3VA Awards 243 7 Million for New Hampshire Veterans Home 48212 1HMS Holdings Corp to Present at William Blair 29th Annual Growth Stock Conference 48209 1
... the University of Wisconsin-Madison is using musi... species in the state. , "Research shows music ...g memory, emotion, attitudes, and even behavior," ...es communication at UW-Madison and environmental c...w, who directed the project, recruited a group of ...
...008 SRI International announced today that it has ...s grant from the Bill & Melinda Gates Foundation. ...h research project conducted by Krishna Kodukula, ...enter for Advanced Drug Research (CADRE) in Shenan...ociate director of Proteomics and Protein Biochemi...
...he University of Houston to use technologies with ...tools that will help doctors and technicians bette...d neck cancer. , Dr. Ali Kamrani, founding direct...ory at UH and a former auto industry researcher, i...r and deputy research director of radiation physic...
Other Biology News:SRI International receives $100,000 Grand Challenges Explorations grant 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4
Customized Competent E. coli. from Molecular Cloning Laboratories (MCLAB)
Fluorescent Standards Red Standard from Invitrogen
X-Gal from GE Healthcare, formerly Amersham Biosciences
Mouse Anti-Oligodendrocyte Marker O1 Monoclonal Antibody, Unconjugated, Clone O1 from R&D Systems
Biology Products: